




What is CanAssist Breast?

CanAssist Breast (CAB) is a prognostic test for eligible* breast cancer patients. CAB is performed on patient's tumor sample removed during surgery and provides information about risk of breast cancer recurrence beyond what current conventional methods can offer. CAB determines whether a patient has **"low- or high-risk"** of breast cancer recurrence, which helps oncologists in deciding use of chemotherapy and/or additional therapies.

How CAB works?



What makes CAB unique?

 <p>First test to be developed and validated on Asian patients</p>	 <p>Large Indian and international validation cohort</p>	 <p>Machine Learning-based algorithm</p>	 <p>Renowned validation partners in India, USA and Europe</p>
 <p>5 year prospective Real world use of CAB shows accuracy of 98%</p>	 <p>Patented combination of biomarkers</p>	 <p>CAP accredited ISO 13485 accredited</p>	 <p>Published & presented in major international journals & conferences</p>

***Early invasive breast carcinoma** Early invasive breast carcinoma (T1N0, T2N0, T1N1, T2N1, T3N0) who have hormone-receptor positive and HER2-negative tumours with 0-3 positive lymph nodes and of any tumour grade.

Turn around time:
8 working days

Download CanAssist Breast publications:



Clinical Breast Cancer
(August 2025)



Scientific Reports
(August 2025)



Therapeutic Advances
(May 2025)